Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: Clinical results from an open study

References

• Amato, L, Minozzi, S, Davoli, M, Vecchi, S, Ferri, M, Mayet, S. 2004. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews: CD004147.
   Google Scholar
• Boulton DW, Arnaud V, DeVane CL. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 2001; 70: 48–57
   PubMed Web of Science ®Google Scholar
• Breen CL, Harris SJ, Lintzeris N, Mattick RP, Hawken L, Bell J. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend 2003; 71: 49–55
   PubMed Web of Science ®Google Scholar
• Caplehorn JRM, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse 1996; 31: 177–196
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opiod dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 9
   Web of Science ®Google Scholar
• Crettol S, Déglon J-J, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80(6)668–681
   PubMed Web of Science ®Google Scholar
• Cronbach LJ. Designing evaluations of educational and social programs. Jossey-Bass, San Francisco, CA 1982
   Google Scholar
• Darke S, Degenhardt L, Mattick R. Mortality amongst illicit drug users. Epidemiology, causes and intervention. Cambridge University Press, Cambridge 2007
   Google Scholar
• De Vos JW, Ufkes JG, Kaplan CD, Tursch M, Krause JKA, van Wilgenburg H, et al. l-Methadone and d,l-methadone in methadone maintenance treatment for opiate addicts: a comparison of therapeutic effectiveness and plasma concentrations. Eur Addict Res 1998; 4: 134–141
   PubMed Web of Science ®Google Scholar
• Eap CB, Finkbeiner T, Gastpar M, Scherbaum N, Powell K, Baumann P. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividuell variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Pharmacol 1996; 50: 385–389
   Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone. Clin Pharmacokinet 2002; 41(14)1153–1193
   PubMed Web of Science ®Google Scholar
• Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone. Arch Intern Med 2006; 166: 1280
   PubMed Web of Science ®Google Scholar
• Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R) and (S) methadone in methadone maintenance patients. Br J Pharmacol 2000; 50: 427–440
   Web of Science ®Google Scholar
• Foster DJ, Somogyi AA, White JM, Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone maintenance patients. Br J Pharmacol 2004; 57: 742–755
   Web of Science ®Google Scholar
• Glasper A, Reed LJ, de Wet CJ, Gossop M, Bearn J. Induction of patients with moderately severe methadone dependence onto buprenorphine. Addict Biol 2005; 10: 149–155
   PubMed Web of Science ®Google Scholar
• Gowing, L, Ali, R, White, J. 2006. Buprenorphine for the management of opiod withdrawal. Cochrane Database of Systematic Reviews: CD002025.
   Web of Science ®Google Scholar
• Greenwald MK, Schuh KJ, Stine SM. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study. Am J Addict 2003; 12: 365–374
   PubMed Web of Science ®Google Scholar
• Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58: 503–508
   PubMed Web of Science ®Google Scholar
• Hulse GK, English DR, Milne E, Holman CDJ. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94: 221–229
   PubMed Web of Science ®Google Scholar
• Judson BA, Horns WH, Goldstein A. Side effects of levomethadone and racemic methadone in a maintenance program. Clin Pharmacol Ther 1976; 20: 445–449
   PubMed Web of Science ®Google Scholar
• Justo D. Methadone-induced long QT syndrome vs. methadone-induced torsades de pointes. Arch Intern Med 2006; 166: 2288
   PubMedGoogle Scholar
• Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects on methadone. Clin Pharmacol Ther 2004; 76(3)250–269
   PubMed Web of Science ®Google Scholar
• Kreek MJ, Hachey DL, Klein PD. Stereoselective disposition of methadone in man. Lif Sci 1979; 24: 925–932
   PubMed Web of Science ®Google Scholar
• Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 1996; 18: 221–227
   PubMed Web of Science ®Google Scholar
• Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health 2001; 91: 774–780
   PubMed Web of Science ®Google Scholar
• Mattick, RP, Kimber, J, Breen, C, Davoli, M. 2004. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews: CD002207.
   PubMedGoogle Scholar
• Maxwell JC, Pullum TW, Tannert K. Deaths of Clients in methadone treatment in Texas: 1994–2002. Drug Alcohol Depend 2005; 78: 73–81
   PubMed Web of Science ®Google Scholar
• Mitchell TB, Dyer KR, Newcombe D, Salter A, Somogyi AA, Bochner F, et al. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S-) vs. (R-) methadone exposure. Br J Pharmacol 2004; 58: 609–617
   Web of Science ®Google Scholar
• Nakamura K, Hachey DL, Kreek MJ, Irving CS, Klein PD. Quantification of methadone enantiomers in humans using stable isotope-labeled (2H3)- and (2H8)methadone. J Pharmac Sci 1982; 71: 40–43
   PubMed Web of Science ®Google Scholar
• Scherbaum N, Finkbeiner T, Leifert K, Gastpar M. The efficacy of l-methadone and racemic methadone in substitution treatment for opiate addicts – a double–blind comparison. Pharmacopsychiatry 1996; 29: 212–215
   PubMed Web of Science ®Google Scholar
• Soyka M. Safety aspects in methadone maintenance treatment – part 1 (in german). Suchtmed 2008; 10: 7–27
   Google Scholar
• Soyka M, Apelt SM, Wittchen HU. The insufficient involvement of psychiatrists in substitution treatment (in German). Nervenarzt 2006a; 77: 1368–1372
   PubMed Web of Science ®Google Scholar
• Soyka M, Apelt SM, Lieb M, Wittchen HU. One year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: A nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006b; 26: 657–660
   PubMed Web of Science ®Google Scholar
• Soyka M, Banzer K, Erbas B, Koller G, Backmund M. Substitution treatment of drug addicts: legal requirements and new evidence from therapy research (in German). Nervenheilkunde 2006c; 25: 286–294
   Google Scholar
• Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of substance use and related disorders, part I: Alcoholism. World J Biol Psychiatry 2008; 9: 6–23
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing International HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005; 100: 150–158
   PubMed Web of Science ®Google Scholar
• Termorshuizen F, Krol A, Prins M, van Ameijden EJC. Long-term outcome of chronic drug use. Am J Epidemiol 2005; 161: 271–279
   PubMed Web of Science ®Google Scholar
• Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007; 321(1)389–399
   PubMed Web of Science ®Google Scholar
• United Nations Office for Drug Control. 2006. World drug report 2006. New York: United Nations Publications.
   Google Scholar
• Verthein U, Ullmann R, Lachmann A, Düring A, Koch B, Meyer-Thompson H-G, et al. The effects of racemic D,L-methadone and L-methadone in substituted patients – a randomized controlled study. Drug Alcohol Depend 2005; 80: 267–271
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Gölz J, et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients. Drug Alcohol Depend 2008; 95: 245–257
   PubMed Web of Science ®Google Scholar
• West SL, O'Neal KK, Graham CW. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 2000; 12: 405–414
   PubMedGoogle Scholar
• White JM, Lopatko OV. Opioid maintenance: a comparative review of pharmacological strategies. Expert Opin Pharmacother 2007; 8: 1–11
   PubMed Web of Science ®Google Scholar